LIFNano-Rx's Board grows in strength with David Leppert M.D. - world-renowned MS neurologist and corporate Global Medical Officer - taking up position as Director

Professor Leppert's achievements include having led the development of OCREVUS (ocrelizumab: Roche) and KESIMPTA (ofatumumab: Novartis) for Multiple Sclerosis through Phase 3 Clinical Trials - bringing a step-change to treatment. OCREVUS is the first FDA-approved product for primary progressive multiple sclerosis.

David continues to lead introduction of neurofilament light chain (NfL) as a biomarker of nerve damage with the potential to allow personalised therapeutic decision making in progressive MS. In June 2021 the FDA provided a Letter of Support for development of NfL in progressive MS - the first FDA Letter of Support for further research of any MS-specific biomarker for use in clinical trials.

"We are immensely fortunate to have attracted Professor Leppert into our Team" says Florian Kemmerich, Chairman of LIFNano-Rx "Especially as we approach clinical trials where David's input will be pivotal in delivering the healing power of LIFNano to people with MS". Su Metcalfe, CEO, adds "In joining our Board, LIFNano-Rx gains a rare leader in David, capable of delivering new approaches to the clinic based on a deep understanding of the disease process in MS". David comments "LIFNano's approach to treat MS is the first to work with the body's own pathways with potential to heal the lesions of MS and switch off immune attack against myelin - the root cause of MS"

Professor Leppert became involved with LIFNano-Rx when supporting Su's recent funding bid to the National Multiple Sclerosis Society, together with Professor Gavin Giovannoni of Queen Mary's London and Professor William Banks of Washington State University USA. Currently short-listed, the outcome of this bid will be announced in June 2022.